AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Biospace

Published November 4, 2026

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November ...

Read the full story at Biospace

Psychedelics · Compass to submit psilocybin depression drug for approval imminently after stock wobbles. November 3, 2026. ·. 2 min read. ·. Heather.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics